Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

In the 17-week INHALE-3 trial, 123 adults with type 1 diabetes were randomly assigned to technosphere insulin plus insulin degludec (Tresiba, Novo Nordisk) with use of a Dexcom G7 continuous ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

DexCom has a significant (and expanding ... CGM devices in the U.S. were available only through prescription and primarily to type 1 diabetes patients or those with type 2 who need insulin.

Dexcom State of Type 2 Report: Access and Attitudes Across ... new Dexcom G7 15 Day sensor1 will be presented on March 20 at 1 p.m. CET in Hall D. With a MARD of 8.0%,2 Dexcom G7 15 Day will ...

Treatments for Type 2 diabetes and new clinical trial data ... Here are three highlights from the first day of the conference: 1. Dexcom previews new data for 15-day glucose monitor Dexcom shared ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 ...